14 March 2023 - GSK today announced that the China National Medical Products Administration has accepted for review a new drug application for Nucala (mepolizumab) as an add-on maintenance treatment for severe eosinophilic asthma. 

If approved, Nucala would be the first targeted anti-interleukin-5 (IL-5) treatment in China for adult and adolescent patients with this condition.

Read GSK press release